Navigation Links
Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Date:3/18/2009

---- ---- NET CASH FLOWS USED IN OPERATING ACTIVITIES (413) (2,939) NET CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES (399) 3,083 EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH (140) (289) NET CHANGE IN CASH AND CASH EQUIVALENTS (952) (145) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 5,723 5,868 ----- ----- CASH AND CASH EQUIVALENTS AT END OF PERIOD $4,771 $5,723 ====== ====== Transgenomic, Inc. Summary Financial Results Unaudited Condensed Consolidated Balance Sheets (dollars in thousands) December December 31, 2008 31, 2007 -------- -------- ASSETS CURRENT ASSETS: Cash and cash equivalents $4,771 $5,723 Accounts receivable (net of allowances for bad debts of $388 and $703, respectively) 5,385 5,095 Inventories 4,775 4,586 Prepaid expenses and other current assets 654 759 --- --- Total current assets 15,585 16,163 PROPERTY AND EQUIPMENT, NET 1,198 1,579 OTHER ASSETS: Goodwill
'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Transgenomic, Inc. Forms Scientific Advisory Board
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a net loss allocable to common stockholders in ... per share, compared to a net loss allocable to common ... or $0.75 per share. "Receiving the positive lorcaserin BLOOM results ...
... the Digital Arts AllianceBATON ROUGE, La., May 11 ... the second year in a row, Louisiana State University,s ... program with scholarships and digital arts equipment. The 2009 ... video cameras to document their experiences and pass them ...
... FREMONT, Calif., May 11 Quark Pharmaceuticals, ... developing novel RNA interference (RNAi)-based therapeutics, today ... Scientific Officer, presented a study titled, "PF-04523655 ... Retinal Cells Producing Target Gene Knockdown and ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 2Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 3Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3 2Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3 3
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a ... that CEO Mr. Gino Pereira was interviewed on ... in Tampa Florida . Mr. Pereira discusses ... Cedric Harris and how the Wocket™ aims to ... Cedric Harris tells Gino he ...
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... that affect blood pressure were recently identified in ... findings of the study, in which Uppsala University ... Web edition of Nature Genetics . ... of cardiovascular disorders. Previous studies have shown that ...
... (LSTM) has been awarded a 1.1m grant by the ... year project to develop a Field Applicable Screening Tool ... in mosquitoes. The two principal methods for control ... insecticide-treated bednets (ITNs) and indoor residual spraying (IRS) of ...
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2$1.6 million grant to lead development of resistance-detecting field kit 2Does mom know when enough is enough? 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
in vitro Translation, Accessory Products...
Request Info...
Biology Products: